How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
REDWOOD CITY, Calif., March 29, 2016 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Barclays Generic Pharmaceuticals Symposium on Wednesday, April 6 in New York City.
About Coherus BioSciences, Inc.
Coherus is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products, including CHS-5217 (bevacizumab biosimilar) and CHS-3351 (ranibizumab biosimilar). For additional information, please visit www.coherus.com.
CONTACT: Keith Vendola, M.D. Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 437-6239
